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https://doi.org/10.1016/j.celrep.2021.108945SUMMARYBasal breast cancer is associated with younger age, early relapse, and a high mortality rate. Here, we use un-
biased droplet-based single-cell RNA sequencing (RNA-seq) to elucidate the cellular basis of tumor progres-
sion during the specification of the basal breast cancer subtype from the luminal progenitor population in the
MMTV-PyMT (mousemammary tumor virus-polyomamiddle tumor-antigen) mammary tumormodel. We find
that basal-like cancer cells resemble the alveolar lineage that is specified upon pregnancy and encompass
the acquisition of an aberrant post-lactation developmental program of involution that triggers remodeling
of the tumor microenvironment and metastatic dissemination. This involution mimicry is characterized by
a highly interactive multicellular network, with involution cancer-associated fibroblasts playing a pivotal
role in extracellular matrix remodeling and immunosuppression. Our results may partially explain the
increased risk and poor prognosis of breast cancer associated with childbirth.INTRODUCTION
The mammary gland is a unique organ that mostly develops
postnatally, undergoing profound tissue morphogenesis during
puberty and pregnancy (Oakes et al., 2014). During pregnancy,
the transcription factor ELF5 drives the differentiation of the alve-
olar milk-secretory epithelium (Gallego-Ortega et al., 2013;
Oakes et al., 2006, 2008) from the luminal progenitor cell popu-
lation (Shehata et al., 2012; Visvader and Stingl, 2014). Tran-
scriptional profiling at single-cell resolution has recently shown,
however, that this differentiation process is more complex, with
multiple subtypes and states involved in the differentiation of the
alveoli during pregnancy (Bach et al., 2017; Nguyen et al., 2018).
Different mammary epithelial cell lineages have been proposed
as the cell of origin of the breast cancer subtypes (Fu et al.,
2020; Lim et al., 2010; Visvader, 2011), including those with spe-This is an open access article under the CC BY-Ncific genetic aberrations (Lim et al., 2010;Molyneux and Smalley,
2011; Visvader and Stingl, 2014).
Tissue morphogenesis associated with pregnancy and lacta-
tion concludes with the developmental process of mammary
involution, a process whereby the lactating mammary gland re-
turns to a quasi-nulliparous state (Inman et al., 2015; Stein
et al., 2007). Involution is an exquisitely regulated multicellular
process that requires a high degree of cell-to-cell communica-
tion within the mammary epithelium and throughout different
cell types from the tissue microenvironment, encompassing
innate immune control of inflammation, a pseudo-wound-heal-
ing program of activated fibroblasts and intense adipogenesis
(Schedin et al., 2007; Watson and Kreuzaler, 2009).
Developmental processes of mammary remodeling are often
hijacked in breast cancer as drivers of tumor progression (Fan-
tozzi and Christofori, 2006). Pregnancy-associated breastCell Reports 35, 108945, April 13, 2021 ª 2021 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)






OPEN ACCESScancer (PABC) correlates with metastatic disease and poor
prognosis and is generally associated with younger women
(Bladström et al., 2003; Callihan et al., 2013; Daling et al.,
2002; Goddard et al., 2019; Johansson et al., 2011; Schedin,
2006; Stensheim et al., 2009; Whiteman et al., 2004). Despite
the effects of the hormonal load associated with pregnancy,
there is increasing evidence pointing to a direct effect of the
tumour microenvironment (TME) and the events of tissue remod-
eling that occur in the mammary gland during pregnancy, partic-
ularly those associated with involution, as the driving force
behind the higher mortality associated with PABC (Lyons et al.,
2011; Schedin, 2006; Schedin et al., 2007).
We have previously shown that pregnancy-associated tran-
scriptional networks driven by the transcription factor Elf5
specify the basal subtype of breast cancer, promoting a lethal
phenotype, characterized by endocrine insensitivity and resis-
tance to therapy (Kalyuga et al., 2012) and the promotion of met-
astatic dissemination through a profound alteration of the TME
(Gallego-Ortega et al., 2015). Here, we use spatially and time-
controlled induction of Elf5 within the epithelial cells of MMTV-
PyMT mammary tumors to study tumor progression mecha-
nisms associated with the specification of the basal breast can-
cer subtype at single-cell resolution. Our analysis revealed
intense tumor cell diversity, and despite the majority of cancer
cells being of luminal origin, we identified additional cell classes
that present markers typically found in myoepithelial and basal
lineages. Besides the contribution of cell-intrinsic cues of the
alveolar cell differentiation to breast cancer progression (Chak-
rabarti et al., 2012; Kalyuga et al., 2012), we exposed additional
cell-extrinsic effects on the TME (Gallego-Ortega et al., 2015),
such as epithelial-mesenchymal transition (EMT), collagen
deposition, inflammation, vascular leakiness, and hypoxia.
Finally, we uncovered an involution mimicry process associated
with tumor progression elicited by alveolar cancer cells. This
multicellular mechanism encompasses immune suppression
by recruiting of myeloid-derived suppressor cells (MDSCs) and
the activation of specific subpopulations of cancer-associated
fibroblasts (CAFs).
RESULTS
Unbiasedmassively parallel single-cell RNA sequencing
(scRNA-seq) captures cell heterogeneity ofMMTV-PyMT
mammary tumors
In this study, we used two mouse models, the MMTV-PyMT
mouse mammary tumor model (PyMT/WT) and a mammaryFigure 1. High-resolution cell composition of MMTV-PyMT tumors
(A) Top-expressed genes contributing to the epithelial (red), stromal (blue), and im
signatures of the xCell algorithm. Right: boxplot for the distributions of all cells fr
(B) Representative contour plot of the cell composition of a PyMT tumor ana
EpCAM/CD45 (stroma).
(C) t-distributed stochastic neighbor embedding (tSNE) plot of PyMT tumors colo
each of the main cell lineages.
(D and E) tSNE plot of the distribution of cells per genotype (D) and cell clusters d
(bottom).
(F) Cluster tree modeling the phylogenic relationship of clusters in each cell linea
(G) Cell identification score values (xCell algorithm) of the cell clusters in the imm
See also Figures S1–S3, Tables S1 and S2, and Video S1.restricted (MMTV) doxycycline-inducible (rtTA) Elf5 PyMT model
(PyMT/ELF5) (Gallego-Ortega et al., 2015; Guy et al., 1992; Lin
et al., 2003; Maglione et al., 2001; Oakes et al., 2008) (Fig-
ure S1A). Consistent with previous reports, specific induction
of Elf5 in the mammary gland epithelium of PyMT tumors
increased lung metastases and induced leaky vasculature (Fig-
ures S1B–S1D; Videos S1 and S2) (Gallego-Ortega et al.,
2015). Eleven mouse mammary tumors at endpoint (14-week-
old FBVn background) from the MMTV-PyMT/WT and PyMT/
ELF5 models were harvested and analyzed using Drop-seq
(Macosko et al., 2015). Cells passing quality control (QC) filter
(15,702) (Figures S2A and S2B) contributed to all cell clusters,
indicating consistent sampling between replicates (Figure S2C).
As expected, Elf5 expression was higher in PyMT/ELF5 tumors
(Figure S2D). The presence of major cell lineages was annotated
using gene expression metasignatures (Aran et al., 2017),
defining epithelial cells (63.16%), stroma (20.41%), and tumor-
infiltrated immune cells (16.44%). These lineages showed con-
sistency among tumor replicates (Figure 1A; Table S1) and
were confirmed with cell surface classification by flow cytometry
(Figure 1B). A tSNE visualization of the three main cellular com-
partments and their associated top-expressed and canonical
markers is shown in Figure 1C and Figure S3A, respectively.
This dataset is accessible in an interactive Shiny application
(see Additional resources in the STAR Methods).
Consistentwith the role of Elf5 as amaster regulator of the alve-
olar cell specification (Gallego-Ortega et al., 2013; Oakes et al.,
2008), induction of Elf5 expression in PyMT tumors generated a
profound transcriptional redefinition of the epithelial cell
compartment, which was not observed in the other lineages
(Figure 1D).
Characterization of the cell diversity of each main lineage
basedondifferential geneexpression analysis andk-meansclus-
tering (Figure 1E; Table S2) revealed two families in the immune
compartment (T/natural killer [NK] cells and B/myeloid cells),
three in the stromal compartment (endothelium and several fibro-
blast classes) and two in the cancer compartment; all of them
were defined early in the phylogeny (Figure 1F). The top differen-
tial marker genes that define stromal and immune cell compart-
ments re shown in Figure S3B. Such cell diversity was also
confirmedusing the xCell algorithm (Aran et al., 2017) (Figure 1G).
PyMT cancer cell diversity resembles aspects of
different mammary epithelial lineages
To further explore Elf5 action in PyMT tumors, we subset and re-
clustered the epithelial cell compartment (6,475 PyMT/WT andmune (green) clusters and their percentage. Bottom panel: heatmaps for the
om all replicates in the three main compartments. Error bars show SEM.
lyzed by flow cytometry, EpCAM+ (epithelial cells), CD45+ (leukocytes), and
red by main cell lineage. The dot plot shows the top differential markers from
efined by a k-means-based clustering algorithm (E) and their relative frequency
ge at increasing resolutions. Dashed red line shows the resolution chosen.
une and stromal compartment.
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OPEN ACCESS3,233 PyMT/ELF5 cells), revealing intense heterogeneity with 11
epithelial clusters (Figure 2A; Table S2; see also the Shiny applica-
tion). The strong genotype-driven cell enrichment in the epithelial
compartment (Figure2B)wasnotdue tobatcheffects (FigureS3C).
Epithelial cluster 1 (C1) and C6 were formedmostly in response to
forced Elf5 expression, while C0, C7, C9, C4, and C3 were most
abundant in wild-type (WT) cells (Figure 2C), a distribution consis-
tent with Elf5 expression in these clusters (Figure S3D). Concomi-
tantly, flow cytometry analysis of cancer epithelial cells revealed
thatELF5 forceddifferentiation of the luminal progenitors (Shehata
et al., 2012) within the luminal population (Figure 2D).
We then annotated the cells from our MMTV-PyMT epithelial
clusters using previously defined canonical markers of the
mouse mammary epithelium (Bach et al., 2017) (Figure 2E). C0
and C7 expressed genes consistent with Procr+ multipotent/
stem cells. C9 cells expressed hormone-sensing (Hs) lineage
markers, C8 expressed markers for basal (B)/myoepithelial
(Myo) cells; C1, C2, C3, C4, and C6 presented markers consis-
tent with luminal cells, with C2, C3, and C4 presenting progenitor
markers, while C1 and C6 presented markers consistent with
differentiated alveolar cells. C5 corresponded with cycling cells
(Figure S3E), and C10 showed low PyMT oncogene expression
levels (Figure S3D), suggesting an early transformed origin of
normal cells trapped within the tumor mass. A complete func-
tional annotation of each epithelial cluster using gene-set varia-
tion analysis (GSVA) (Hänzelmann et al., 2013) can be found in
Table S3 and Data S1 and S2.
Trajectory analysis reveals that Elf5 drives an alveolar
basal-like cell fate on PyMT tumors
To further investigate the dynamic states present the PyMT tu-
mors, we performed pseudotime trajectory analysis along the
mammary gland hierarchy gene signature (Pal et al., 2017), iden-
tifying seven discrete states (Figure 2F, upper panels). Elf5 had a
profound impact upon the structure of epithelial cell diversity,
biasing the composition of the cell lineages toward one of the
end-fate axes (right-hand side) of the pseudotimeplot dominated
by state 1 (S1) at the expense of a depletion of S2, S4, S5, andS6.
Overlayof thecell cluster identity (C)with thepseudotiming states
(S) (Figure 2F bottom panels, and Figure 2G) confirmed that the
alveolar lineage state (red, S1) corresponded to two distinct cellFigure 2. Cancer epithelial cell diversity of PyMT tumors
(A) tSNE plot of the epithelial cell groups defined by k-means clustering analysis
(B) Distribution of cells by genotype.
(C) Contribution the genotypes to each cell clusters. Cluster numbers are colore
(D) Representative flow cytometry plots of one of the replicates defining the per
quantification (right) (WT, aqua, n = 6; ELF5, red, n = 5; unpaired t test, ***p < 0.0
(E) Dot plot representing the expression level (red jet) and the number of express
each PyMT epithelial cluster as defined by Bach et al. (2017), including hormo
progenitor (LP), alveolar differentiated (Alv-d), alveolar progenitor (Alv-p), basal (
(F) Top: pseudotime analysis of the PyMT/WT and /ELF5 cancer epithelial cells alo
of the pseudotime states into tSNE clustering coordinates.
(G) Schematic representation of the overlayed cell states (S) and cluster cell iden
(H) GSVA score for the gene signatures that define the main mammary gland linea
representations of each metasignautre for LP, basal, and ML. The top bar shows
(I) Frequency of the different cell lineages in each genotype.
(J) Illustration of cell diversity of PyMT tumors based on the canonical structure
See also Figure S3, Tables S2 and S3, and Data S2.identities (C1 and C6); the sensor lineage state (pink, S7) was
composed of C9, and the myoepithelial/basal lineage state (pur-
ple, S6) was formed by C7 and C8. An undifferentiated state with
multipotent/stem characteristics (blue, S5), which correspond to
C0, sat in a position equidistant from the myoepithelial and the
luminal lineages (alveolar and sensor). Interestingly, and consis-
tent with the literaturewhere stemcell properties are confounded
bymyoepithelial properties (Prater et al., 2014), C7was classified
as part of the basal/myoepithelial lineage; however, this cluster
presents strong multipotent characteristics similar to those pre-
sent in C0. The luminal progenitor state (brown, S2, represented
byC2,C3, andC4) presented subtle differential featureswithin its
clusters, presumably due to their strong plasticity.
Trajectory analysis was complemented by GSVA and meta-
signature visualization (Figure 2H). The luminal progenitor popu-
lation was derived fromCD29loCD24+CD61+mammary epithelial
cells; thus, it contains progenitors of both the Hs and alveolar lin-
eages (Sheridan et al., 2015). These analyses associated C2with
the alveolar lineage, suggesting its identity as a pre-alveolar
committed luminal progenitor, or a cell type that sits in the transi-
tion zone between the luminal progenitor and the alveolar line-
ages. Similarly, C4 was associated with the Hs lineage repre-
sented by C9, indicating a luminal progenitor committed toward
this lineage. In this scenario, C3 remained undefined, so we clas-
sified it as an uncommitted luminal progenitor. The distribution of
the different designated lineages in the two genotypes (Figure 2I),
which showed less heterogeneity in PyMT/ELF5 tumors induced
by a strong enrichment of the alveolar lineage, suggesting a
skewing toward alveolar lineage differentiation.
Altogether, this analysis identified a large luminal lineage as
previously demonstrated in bulk RNA sequencing (RNA-seq)
(Lim et al., 2010). However, our single-cell-resolution data re-
vealed further cancer cell diversity and underscored strong cell
plasticity (Figure 2J). PyMT/ELF5 tumors, on the other hand,
were less heterogeneous and dominated by the alveolar lineage.
Molecular mechanisms of cancer progression
associated with cancer cells of alveolar origin
We next sought to validate some of the functional findings found
in cancer cells of alveolar origin (C1 and C6), which were charac-
teristic of PyMT/ELF5 tumors..
d by the dominant genotype (>2-fold cell content of one genotype).
centage of alveolar and luminal progenitors for each genotype (left) and their
01, **p < 0.01); error bars show SEM.
ing cells (dot size) of the transcriptional mammary gland epithelium markers in
ne-sensing differentiated (Hs-d), hormone-sensing progenitor (Hs-p), luminal
B), myoepithelial (Myo), and undifferentiated (Multi).
ng the trajectory of the mammary gland epithelial hierarchy. Bottom: projection
tities (C).
ges (basal, LP, and mature luminal [ML]) for each of the clusters. Bottom: tSNE
the assigned mammary epithelial cell type as per (G).
of the mammary gland epithelial lineages.
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OPEN ACCESSCell-cycle marker signatures (Tirosh et al., 2016) identified a
specific group exclusively populated by cells in G2M or S phase
of the cell cycle (Figure 3A). PyMT/ELF5 tumors showed enrich-
ment in the G1 phase, and this is consistent with our previous re-
ports of cell-intrinsic effects of Elf5 increasing cell-cycle time by
delaying entry into S phase (Kalyuga et al., 2012), as well as a
report that Elf5 reduced cell proliferation in PyMT tumors (Gal-
lego-Ortega et al., 2015).
GSVA for specific signatures of known functions of Elf5 and
functions suggested by the hallmark analysis from Data S2 and
Table S3 revealed strong enrichment of lactation, involution,
and hypoxia pathways and a decrease in EMT in PyMT/ELF5 tu-
mors (Figure 3B). This was confirmed by an association of the
EMT signature restricted to myoepithelial and undifferentiated
cells and is consistent with previous reports showing cell-
intrinsic effects of Elf5 (Chakrabarti et al., 2012) and a decrease
in the mesenchymal marker vimentin in whole lysates of PyMT/
ELF5 tumors at the protein level (Figure 3C).
Cells enriched for a hypoxic gene signature concentrated in
myoepithelial and alveolar cell clusters (Figure 3D; Data S2; Ta-
ble S3), and this is consistent the with intense vascular leakiness
of PyMT/ELF5 tumors (Figure S1D) (Gallego-Ortega et al., 2015).
Immunohistochemistry (IHC) with hypoxyprobe-1 identified
extensive hypoxic areas within PyMT/ELF5 tumors, underscor-
ing the extensive tissue remodeling effects of the specification
of the basal-like alveolar epithelium (Figure 3D).
As expected, the lactation signature was strongly enriched in
cellsofalveolarorigin (Figure3E). IHCrevealedastrongproduction
of milk in PyMT/ELF5 tumors compared to PyMT/WT tumors and,
to a similar extent, a lactating normal mammary gland (Figure 3E).
In the normal mammary gland, milk stasis generates the signals
that trigger mammary involution. In this scenario, where milk
cannot leave the tumor, we identified a late-involution gene signa-
ture (Stein et al., 2004) associatedwith the luminal lineage in PyMT
tumors, specifically enriched in Elf5 alveolar cells (Figure 3E).
These results point out to a mechanism of involution mimicry
as a plausible driver of the cell-extrinsic effect of Elf5 remodeling
of the TME and the acquisition of aggressive traits of tumor pro-
gression associated with the transition of the luminal-to-basal
subtype of breast cancer.
Characterization of CAFs in PyMT tumors
Involution is a multistep and multicellular process that involves
alveolar cell death and tissue remodeling, the latter orchestrated
by stromal and immune cells (Watson, 2006). Among these cellFigure 3. Orthogonal validation of cancer-related features associated
(A) tSNE plot of the cell-cycle stages of the PyMT cancer cells. Circled area show
grouped by genotype is shown in the bar chart.
(B) GSVA analysis of gene expression meta-signatures of cancer-related and Elf
(C) tSNE plot of the EMT metasignature. Right: western blot of canonical EMT m
lysates.
(D) tSNE plot of the hypoxia metasignature, and boxplot (bottom) of the extensio
sections (tumors and lung metastasis) stained using IHC based on hypoxyprobe
****p < 0.0001. Error bars show SEM.
(E) tSNE plots for lactation and late involution (stage 4 [S4]) metasignatures. An
compared with a mammary gland from an aged-matched virgin mouse and in P
Scale bars (D and E), 200 mm.
See also Figure S1, Table S3, and Data S2.types, fibroblasts have a critical role during the extracellular ma-
trix (ECM) remodeling and immune suppression steps (Guo et al.,
2017b). Thus, we further explored the role of CAFs in aberrant
involution in our model as a potential key event that could fuel
Elf5-driven metastasis.
Unsupervised clustering of the fibroblast subset (2,255 cells
from PyMT/WT and PyMT/ELF5 tumors) revealed three major
fibroblast clusters (Figures 4A, S4A, and S4B; Table S2),
including a fibroblast subset from C2 enriched for a G2/M signa-
ture (Figure S4C; see also the Shiny application).
CAFs are known to be highly diverse, which was confirmed in
our system, as canonical fibroblast markers (Cortez et al., 2014)
failed to specify= any particular transcriptomically defined fibro-
blast cluster (Figure S4D). Previous unbiased scRNA-seq ana-
lyses in human tumors have classified two major fibroblast sub-
types (Lambrechts et al., 2018; Puram et al., 2017): (1) activated
myofibroblasts, involved in tissue remodeling architecture by
physical forces; and (2) secretory CAFs, related to ECM synthe-
sis and cyto- and chemokine production (Kalluri, 2016). Fibro-
blast cluster 0 (CF0) and CF1 were enriched for a secretory
CAF signature, while the activated myofibroblast signature was
concentrated in CF2 (Figure 4B). Functional annotation using
GSVA (Figure S5A) and metasignatures (Davidson et al., 2018)
(Figure 4C and D) of the secretory CAFs identified a remodeling
function for CF0 (i.e., ECM-CAFs), with a desmoplastic signature
of genes involved in ECM interactions, and an inflammatory-
related function for CF1 (i.e., iCAFs), featuring genes involved
in cytokine-cytokine receptor interactions, monocyte recruit-
ment, and the complement cascade (Davidson et al., 2018).
CF2 was enriched for a contractile signature, characterized by
the expression of genes involved in actin cytoskeleton organiza-
tion, and thus identified with myofibroblasts.
This classification is consistent with the recently reported
nomenclature from the PyMT model (Bartoschek et al., 2018)
(Figures S4E and S4F).
CAFs from PyMT/ELF5 mammary tumors show features
of involution mimicry
Unsupervised clustering of the fibroblasts found in PyMT tumors
further identified several subclasses of secretory and contractile
fibroblasts (Figure 4E; Table S2). Involuting mammary fibroblasts
have unique properties that include a high production of fibrillar
collagen, ECM remodeling, and immune suppression through
monocyte recruitment (Guo et al., 2017b). This specialized class
of fibroblasts involved in involution is characterized by thewith PyMT/ELF5 tumors
s the cycling cluster. The quantification of the proportion of cells in each stage
5-related hallmarks associated with PyMT/WT (aqua) and /ELF5 (red) tumors.
arkers (E-Cadh, E-cadherin; Vim, vimentin) on PyMT/WT or /ELF5 full tumor
n of the hypoxic areas in PyMT/WT (aqua, n = 5) and /ELF5 (red, n = 5) tissue
binding. Representative images are shown in the right panels. **p < 0.01 and
ti-milk IHC pictures from a lactating mammary gland at established lactation
yMT/WT and /ELF5 tumors.
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OPEN ACCESSexpression of Col1a1, Cxcl12, Tgfb1, and Mmp3. Increased
fibrillar collagen and Cxcl12 expression are also considered
markers of CAF activation (Sun et al., 2010). We used IHC to
confirm the simultaneous upregulation of three of these markers
in fibroblasts during mammary gland involution (Figure S6). In
PyMT tumors, we identified a group of ECM-CAFs (cluster F3)
and iCAFs (cluster F2), with high expression of three of these invo-
lutionmarkers (Col1a1,Cxcl12, andMmp3) in PyMT/ELF5 tumors,
(Figure 4F), hereafter referred to as involution iCAFs (F2) and invo-
lution-ECM-CAFs (F3). The complete classification of PyMT fibro-
blasts is shown in Figure 4G. Both involution CAFs were enriched
in PyMT/ELF5 tumors (Figure 4H), and this was not due to batch
effects (Figure S5B). Consistently, GSVAs of the CAF-involution
signature and involution marker genes were significantly enriched
in the CAFs from PyMT/ELF5 tumors (Figure 4I).
The functional annotation of the involution fibroblasts revealed
specific differences within the ECM-CAF or iCAF subpopulations
(Figure S5C). For example, involution ECM-CAFs showed unique
fatty acid metabolism and peroxisome hallmarks, suggesting
that these cells may correspond to adipocyte-like fibroblasts
(Bochet et al., 2013). Involution iCAFs showed pathways linked
to a wound-healing process, including inflammation through
the complement cascade and coagulation (Amara et al., 2008;
Lilla et al., 2009; Stein et al., 2004). All of these processes of invo-
lution CAFs commonly occur during late involution (Martinson
et al., 2015; Watson, 2006; Zwick et al., 2018).
We validated the role of CAFs in ECM remodeling bymeasuring
the deposition of collagen in tumor sections using microscopy.
PyMT/ELF5 tumors showed increased fibrillar collagen coverage
compared with PyMT/WT tumors (Figures 5A and 5B), with a
significantly higher proportion of thicker and mature collagen fi-
bers than (Figure 5C), and a more complex spatial arrangement
(peak alignment ±10 degrees from peak) (Figure S7A).
Subsequently, we histologically mapped the location of the
involution CAFs in PyMT tumors by IHC (Figure 5D) using the
proposed involution-CAF markers transcriptionally identified
(Col1A1,Mmp3, and Cxcl12) (Figure S7B). We used an antibody
only recognizing monomer alpha-1 type 1 collagen prior fiber as-
sembly, thus labeling the collagen-I-producing cells. Both
COL1A1- and CXCL12-expressing fibroblasts were infiltrated
throughout the cancer epithelial foci and organized in clusters,
especially in PyMT/ELF5 tumors, where these cells were also
more abundant (Figures 5D and S7C). MMP3 IHC staining shows
positive expression in both intra-foci stromal cells and adjacentFigure 4. Cancer-associated fibroblast (CAF) diversity in PyMT tumors
(A) tSNE plot defined by k-means clustering analysis of the fibroblast subpopula
(B) tSNE plots of the metasignatures of the secretory CAFs and myofibroblasts.
(C) Desmoplastic, inflammatory, and contractile metasignatures.
(D) Violin plots displaying marker genes for each of the three fibroblast clusters de
(CF2).
(E) tSNE plot defined by unsupervised clustering analysis showing heterogeneity
(F) tSNE plot of the involution metasignature. Bottom: violin plots on the nine fib
(G) Cell tree classification of the main lineages of CAFs.
(H) tSNE plot for the distribution of fibroblasts by genotype (ELF5, red; WT, aqu
numbers are colored by the dominant genotype (>2-fold cell content of one gen
(I) GSVA enrichment analysis of involuting mammary fibroblast metasignatures
Mmp3, and Col1a1 genes in all fibroblasts of each genotype.
See also Figures S4–S6 and Table S2.epithelium but negative expression in epithelial areas away
from the stroma. This gradient is consistent with a paracrine ef-
fect of MMP3 secretion from involution CAFs (Figures 5D and
S7C), and it was more noticeable in the PyMT/ELF5 tumors
compared to the PyMT/WT counterparts.
These results functionally and histologically characterize the
increased presence of involution CAFs in PyMT/ELF5 tumors,
confirming the correlation between Col1a1, Mmp3, and Cxc12
mRNA and their protein levels and their utility to identify an invo-
lution process.
Involution signature predicts for poor prognosis in
luminal breast cancer patients in the context of Elf5
expression
Wehave previously shown that luminal breast tumors with higher
expression of ELF5 show basal-like characteristics and poor
prognosis (Gallego-Ortega et al., 2015); thus, these can be
considered the early steps toward the differentiation into a basal
tumor, underscoring ELF5 as a driver of the basal-like pheno-
type. In fact, high ELF5 expression is associated with basal
breast cancers (Kalyuga et al., 2012).
In the METABRIC (Molecular Taxonomy of Breast Cancer In-
ternational Consortium) dataset (Curtis et al., 2012), we
confirmed a significant association between high ELF5 expres-
sion and poorer patient prognosis (Figure 6A), where a higher
proportion of the basal molecular subtype fell into the ELF5-
high group. Similarly, an involution signature predicted for poor
prognosis independent of other pathological characteristics
such as Ki67, basal subtype, and age (<40 years) (Figures 6A
and 6B). Consistent with our hypothesis, patients with higher
expression of ELF5 showed significantly higher levels of expres-
sion of the involution signature, and this was also confirmed in
The Cancer Genome Atlas (TCGA) dataset (Berger et al., 2018;
Cancer Genome Atlas, 2012; Ciriello et al., 2015) (Figure 6C).
Interestingly, in luminal patients, involution mimicry predicted
poor prognosis only in the patient subset with high ELF5 expres-
sion and not in the low-expressing subset (Figure 6D). Taken
together, these results highlight the relationship between ELF5
expression and the involution process in human breast cancer.
Characterization of the cell-to-cell communication
involved in involution mimicry
Involution is amulticellular process; thus,weusedCellphoneDB to
identify cell-to-cell communication networks within PyMT tumorstion as defined in Figure 1E (prefix CF).
fined in (A): ECM-CAFs (CF0), immune-CAFs (iCAFs, CF1), and myofibroblasts
of each of the identified fibroblast species.
roblast clusters for individual genes from the involution signature.
a). Bottom: contribution of each of the genotypes to the cell clusters. Cluster
otype).
associated with PyMT/WT and /ELF5 tumors. Bottom: violin plots of Cxcl12,
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Figure 5. Orthogonal validation of involution
CAFs in PyMT/WT and PyMT/ELF5 tumors
(A) Representative bright-field images and bar
graphs of quantification of total coverage of pic-
rosirius-red-stained PyMT/WT and PyMT/ELF5
tumor sections. n = 4 mice per genotype with 10
regions of interest (ROIs) per tumor.
(B) Representative maximum intensity projections
of second harmonic generation (SHG) signal and
quantification of SHG signal intensity at depth (mm)
(left graph; paired Wilcoxon test) and at peak (right
graph) in PyMT/WT and PyMT/ELF5 tumor sections.
n = 6 mice per genotype with 6 ROIs per tumor.
(C) Polarized light imaging of picrosirius-red-stained
PyMT/WT and PyMT/ELF5 tumor sections and its
quantification. Thick remodeled fibers/high bire-
fringence (red-orange), medium birefringence
(yellow), and less remodeled fibers/low birefrin-
gence (green) are shown. n = 4 mice per genotype
with 10 ROIs.
(D) Representative images (top panels) of the IHC
analysis of COL1A1, MMP3, and CXCL12 in PyMT/
WT and PyMT/ELF5 tumors and their quantification
as percentage of area stained (bottom boxplots).
Black arrows show positive staining on elongated
cells while red arrows show positive staining in
rounded cells. Data correspond to n = 5 tumors with
at least five images per tumor; Scale bars, 100 mm.
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
Scale bars (A–C), 50 mm. Error bars show SEM.
See also Figure S7.
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OPEN ACCESS(Vento-Tormo et al., 2018). CellphoneDB analysis using all cell
clusters defined in this study (Figures 1, 2, and 4; summarized in
Figure S5D) in PyMT tumors revealed a complex interactome
network of cell interactions (Figure 7A). Cellular interconnections
were ranked in three strength levels: (1) fibroblast-fibroblast inter-
actions were the strongest, followed by fibroblast-epithelium con-10 Cell Reports 35, 108945, April 13, 2021nections; (2) endothelium-fibroblast or
-epitheliumand epithelium-epithelium inter-
actions were ranked as mid interactions;
and (3) theweakest connectionswere found
in the immune cell compartment. A com-
plete classification of the predicted cell-to-
cell interactions can be explored using our
HTML-based interactive tool (https://
galdeslab.github.io/CellReportsManuscript/).
These results show a pivotal role of CAFs
as hubs of communication within the TME.
Involution accounts for an interactive
cell network where epithelial cells, fibro-
blasts, and immune cells are the key
players (Watson, 2006). In our model,
ECM-CAFs (both involution and ECM-
CAFs 2) and involution iCAFs showed the
strongest connections (Figure 7B, 1st and
2nd tier, blue lines) with the two Elf5-en-
riched-alveolar epithelial cells clusters,
myoepithelial cells, and luminal progenitor
Hs cells. In the immune interactome(Figure 7B, 3rd and 4th tiers, green lines), the myeloid compart-
ment showed the highest number of connections, communi-
cating with the two Elf5-enriched-alveolar epithelial clusters,
ECM-CAFs (both involution and ECM-CAFs 2), involution iCAFs,
myofibroblasts, and the endothelium. Involution is associated
with the M2-like innate response; thus, these results are in line
(legend on next page)






OPEN ACCESSwith an activated and interactive innate myeloid response
(O’Brien et al., 2010; Stein et al., 2004, 2007).
Further investigation of particular ligand-receptor connections
among CAFs, alveolar epithelial cells, and myeloid cells (Fig-
ure 7C) revealed pathways associated with the multi-functional
aspects of involution (transforming growth factor b [TGF-b]
axis) (Bellomo et al., 2016; Flanders and Wakefield, 2009), net-
works associated with an immune suppressive ecosystem
(Cxcl12 and Dpp4 axis) (Costa et al., 2018; Guo et al., 2017b),
and ECM remodeling (insuline growth factor [IGF] axis) (Black-
stock et al., 2014).
The myeloid cell compartment is also intimately associated
with the process of involution. We have previously demonstrated
that despite their low abundance (Valdés-Mora et al., 2018), tu-
mor-infiltrated MDSCs promote lung metastasis in PyMT/ELF5
tumors (Gallego-Ortega et al., 2015). Our scRNA-seq analysis
mapped the cellular mechanism for MDSC expansion, recruit-
ment, and malignant activation previously described in these tu-
mors (Sevko and Umansky, 2013), identifying the cell of origin of
well-known signaling pathways involved in this process (Fig-
ure 7D). Our results show that MDSC recruitment and malignant
activation in PyMT/ELF5 tumors (Gallego-Ortega et al., 2015) are
driven not only by alveolar cancer cells but also by a complex
molecular intercellular network. Tumor-infiltrated myeloid spe-
cies maintain a feedback loop that enables continuous myeloid
cell recruitment, via Csf3 (G-CSF) and Vegfa, and sustained
inflammation with molecules, including Cxcl1 (also expressed
by other cell compartments) and Cxcl2. CAFs also support
MDSC expansion through Csf1 (M-CSF), Vegfa, Il6, Cxcl12,
and Ccl2 expression and the endothelium with additional Il6
expression.
In summary, the alveolar lineage supports tumor progression,
orchestrating a molecular network of cell-to-cell communication
associated with an inflammatory process of involution mimicry
with malignant CAF activation and immune suppression via
MDSC recruitment (Figure 7E).DISCUSSION
The MMTV-PyMT model gives rise to mammary tumors of
luminal progenitor origin as classified by conventional transcrip-
tomics (Lim et al., 2009, 2010). Our findings, however, under-
score the expansive plasticity of the luminal progenitor compart-
ment, identifying ‘‘malignant states’’ associated with the
mammary epithelial cell lineage specification. Our results unite
tumor heterogeneity with developmental cues and highlight the
intrinsic capacity of tumors to develop distinct molecular sub-Figure 6. Involution signature is a poor prognosis factor and is associ
(A) Kaplan-Meier survival curves from the METABRIC patient cohort in relation
based on top and bottom tertiles. Right panel shows the distribution of the PAM5
patients.
(B) Cox multivariate analysis of METABRIC patient cohort showing hazard ratios
(C) Expression of the involution signature in patients categorized by high and low
TCGA dataset (RNA-seq log10 units). ELF5-high patient tertile (red) and ELF5-lo
(D) Same analysis as (A), but only in luminal patients. Right panels show the influe
panel) subsets of luminal patients. Log-rank p values are shown.
12 Cell Reports 35, 108945, April 13, 2021types, supporting the current understanding of progenitor cells
as the cell of origin of basal and luminal cancers (Visvader, 2011).
Here, we study the functional consequences of the specifica-
tion of the estrogen receptor negative (ER-) basal subtype of
breast cancer through the differentiation from the luminal pro-
genitor cells toward the pregnancy-derived alveolar lineage
(Lee et al., 2013; Oakes et al., 2008). Elf5-specified alveolar can-
cer cells subsequently activate cell-extrinsic mechanisms within
the TME reminiscent of mammary morphogenesis, which were
ultimately associated with the acquisition of tumor progression
cues linked to cancer dissemination, similar to pregnancy-
induced metastasis in the PyMT/WT model (Gallego-Ortega
et al., 2015).
Clinically, patients with luminal tumors receive endocrine ther-
apy as standard-of-care; thus, adoption of the alveolar fate pro-
vides a route of escape from endocrine therapy, as these cells
are insensitive to estrogen and subsequently give rise to a
basal-like tumor (Kalyuga et al., 2012), with much lower survival
rates (Gallego-Ortega et al., 2015). This is consistent with the
identification of Elf5 as the specific marker for a secretory
mature, differentiated luminal cell type, and their associated
gene signatures were highly represented in the basal-like (tri-
ple-negative breast cancer) TNBC patients (Nguyen et al.,
2018). We have found that expression of ELF5 is characteristic
of luminal cancers that are in transit to a basal-like subtype;
thus, breast cancer patients who show higher ELF5 expression
activate involution mimicry pathways that are associated with
poor prognosis. Also, the pro-metastatic effects of Elf5 are
concomitant with mimicry of mammary involution. In this line of
evidence, involution has been previously implicated in the
reduced survival of PABC (Lyons et al., 2011); however, the mo-
lecular drivers of this process had not been fully identified.
Our Elf5-restrictedMMTV-PyMTmodel reproduces the partic-
ular effect of pregnancy on the specification of the alveolar cell
lineage in the context of cancer, shedding light upon the molec-
ular mechanisms involved in these effects of pregnancy in breast
cancer. Mammary involution is a wound-healing-like process
that includes tissue remodeling with fibroblast activation to reor-
ganize the ECM and accommodate the epithelial reduction and
myeloid infiltration to remove all cell fragments (Inman et al.,
2015; Stein et al., 2007). Our data suggest that induced Elf5
expression in cancerous cells stimulates milk production, which
in turn accumulates and triggers an inflammation-mediated TME
remodeling associated with an aberrant involution. This mimicry
involution process results in the loss of alveolar cells that are
rapidly replaced by Elf5-driven differentiation of luminal progen-
itors and a chronic induction of inflammation by involution iCAFs
and myeloid cells encompassing ECM remodeling driven byated with ELF5 expression in breast cancer patients
to ELF5 and involution signature expression. High and low classifications are
0 classification in the top and bottom tertile of ELF5- or involution-expressing
of the involution signature independent of subtype, age, and Ki67 status.
ELF5 expression (tertiles) in the METABRIC dataset (microarray units) and the
w patients (green) are shown.
nce of the involution signature in ELF5-low (top panel) and ELF5-high (bottom
(legend on next page)






OPEN ACCESSinvoluting ECM-CAFs (Figure 7E). As Elf5-driven involution sig-
nals are present in human breast cancers, further work is neces-
sary to assess the potential benefit of targeting involution mim-
icry as a plausible strategy for anti-cancer therapy.
Our scRNA-seq analyses have also allowed us to identify pu-
tative molecular candidates responsible for this epithelium-fibro-
blast-myeloid crosstalk during mimicry of involution (Figure 7C).
We find that only alveolar epithelial cells express Tgfb2 and
Tgfb3 ligands, while their receptor, Tgfbr3, is expressed in invo-
lution CAFs. TGF-b is linked to tumor malignancy by affecting
both cancer cells and the TME, including CAF activation and im-
mune suppression (Bellomo et al., 2016), suggesting that this
could be a specific pathway driving mimicry involution. In fact,
TGF-b3 is induced in response to milk stasis during the first
stage of involution for the induction of alveolar apoptosis, and
TGF-b signaling is also key in the second stage of normal involu-
tion for the induction of ECM deposition and immune suppres-
sion (Flanders and Wakefield, 2009). Altogether, this suggests
that TGF-b signaling might be one of the pivotal pathways trig-
gered by Elf5-alveolar cells and thus a potent pathway for
therapeutic intervention.
We also find specific crosstalk pathways among involution
CAFs, otherCAF-types, and the tumor-infiltrating immunesystem,
which might be activated following this Elf5-mediated TGF-b acti-
vation. Interestingly, involuting mammary fibroblasts that highly
express Cxcl12 induce monocyte recruitment and are associated
with blockade of CD8+ T cell tumor infiltration (Guo et al., 2017a).
Cxcl12 is also a known recruitment factor for MDSCs (Sevko and
Umansky, 2013). Dpp4 is a ligand from one of the iCAFs groups
that could also build the communication bridge between Cxcl12-
expressing involution iCAFs and Cxcl2- and Cxcl10-expressing
myeloid cells. Dpp4 cleaves and inactivates these chemokines,
promoting an immunosuppressive environment by inhibiting the
recruitment of effector T cells (Barreira da Silva et al., 2015) and
promoting chronic inflammation (Sch€urmann et al., 2012). This
also suggests that Dpp4-expressing iCAFs inhibit the M1-innate
response from myeloid cells and fibroblasts.
Thus, our data suggest that during the transition from the
luminal-to-basal breast cancer subtype, alveolar cells orches-
trate a TME remodeling characterized by a mimicry of involution,
resulting in amulticellular process, with the involution CAFs play-
ing a pivotal role in the acquisition of immune suppression and
traits of tumor progression (Figure 7E). Altogether, our data high-
light the relevance of targeting cancer-associated cell species as
a strategy for anti-cancer therapy, an approach particularly
important in the context of PABC.Figure 7. Interactome of PyMT tumors
(A) Heatmap of the cell-cell connections of all cell types from PyMT tumors bas
(myofibroblasts) were pooled together as a single cluster. The scale jet sho
CellphoneDB.
(B) Graphical representation of all significant cell-cell connections identified by Ce
strongest interactions, with a split of 67 (1st tier) and 50 (2nd tier). The immune sy
(C) Representative dot plots of ligand-receptor pairs. Circle size is relative to the n
of each gene, and the blue gradient represents the average scaled expression.
(D) Violin plots of genes from canonical pathways known to recruit and expand M
immune cells.
(E) Proposed molecular model of involution mimicry driven by Elf5 expression.
See also Figure S5.
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Critical commercial assays
Dead Cell Removal Kit Miltenyi Biotec Cat#130-090-101
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PhiX Control v3 Illumina Cat#FC-110-3001
Nextera XT DNA Library kit Illumina Cat#FC-131-1024
Nextseq 500 High Output v.2 kit Illumina Cat#FC-404-2005
NuPAGE 4 to 12% Bis-Tris acrylamide gels Thermo Fisher Scientific Cat#NP0322
BOND Polymer Refine Detection kit Leica Biosystems Cat#DS9800
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Deposited data
Raw data This paper GSE158677
Molecular Taxonomy of Breast Cancer
International Consortium (METABRIC)
Pereira et al., 2016 https://www.cbioportal.org/
The Cancer Genome Atlas (TCGA) Berger et al., 2018; Ciriello et al., 2015;
Cancer Genome Atlas, 2012
https://www.cbioportal.org/
Gene mouse hallmark gene list Subramanian et al., 2005;
Mootha et al., 2003
http://bioinf.wehi.edu.au/software/MSigDB
Experimental models: Organisms/strains
Mouse: FVB/N-Tg(MMTV-PyVT) Guy et al., 1992 N/A
Mouse: FVB/N-Tg(MMTV-PyVT, MMTV-
rTA, TetON-Elf5-IRES-eGFP)
Gallego-Ortega et al., 2015 N/A
Mouse: FVB/NJAusb Inbred strain from Australian
BioResources (origin The
Jackson Laboratory)
MGI Cat# 6200618, RRID:MGI:6200618
Oligonucleotides
Oligos for genotyping: Elf5/EGFP_FW:
GCACCATCTTCTTCAAGGACGAC
This paper N/A
Oligos for genotyping: Elf5/EGFP_RV:
GGTCTTTGCTCAGGGCGGAC
This paper N/A
Oligos for genotyping: rtTA/MTB_FW:
TGCCGCCATTATTACGACAAGC
This paper N/A
Oligos for genotyping: rtTA/MTB_RV:
ACCGTACTCGTCAATTCCAAGGG
This paper N/A
Oligos for genotyping: PyMT_FW:
CGGCGGAGCGAGGAACTGAGGAGAG
This paper N/A
Oligos for genotyping: PyMT_RV:
TCAGAAGACTCGGCAGTCTTAGGCG
This paper N/A
Primers for Drop-seq see Table S4
Software and algorithms
Seurat (v Seurat_2.3.4) Butler et al., 2018 https://satijalab.org/seurat/
Clustering tree Zappia and Oshlack, 2018 https://github.com/lazappi/clustree
Shiny R studio https://shiny.rstudio.com
Monocle (v2 ole) Trapnell et al., 2014 http://monocle-bio.sourceforge.net/
GSVA Hänzelmann et al., 2013 http://www.bioconductor.org/packages/
release/bioc/html/GSVA.html
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CellphoneDB Vento-Tormo et al., 2018 https://www.cellphonedb.org/




Andy’s algorithms Law et al., 2017 https://github.com/andlaw1841/
Andy-s-Algorithm
ImageJ NIH RRID: SCR_003070
MATLAB MathWorks RRID:SCR_001622
GraphPad Prism GraphPad Software RRID: SCR_002798
R v3.4.1 The R Foundation for Statistical
Computing
https://www.r-project.org/
Picrosirius Red birefringence analyzer Vennin et al., 2017 https://github.com/TCox-Lab/
PicRed_Biref
Orientation analysis script Mayorca-Guiliani et al., 2017 https://github.com/TCox-Lab/
Collagen_Orientation
Other














Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, David
Gallego-Ortega (d.gallego@garvan.org.au).
Materials availability
This study did not generate new unique reagents
Data and code availability
The accession number for the Drop-seq data reported in this paper is Gene Expression Omnibus (GEO):GSE158677.
The code generated for the downstream analysis and interactive tools used in this manuscript can be found at https://github.com/
GaldesLab/CellReportsManuscript.
Direct links to interactive visualization tools are:
d CellPhonDB interface https://galdeslab.github.io/CellReportsManuscript/
d Shiny application for Drop-seq data clustering tool https://galdeslab.github.io/CellReportsManuscript/PyMT.html/
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All mice of this study are in a pure FBV/n backgroundwithmore than 20 generations of backcrossing.Micewere bred at the Australian
BioResources Pty Ltd (ABR) facility in Moss Vale, NSW, and housed during the study at the Biological Testing Facility (BTF) at Garvan
Institute’s both under specific pathogen-free conditions. All mice used in this work were females due to the nature of this study
involving breast cancer and pregnancy. All animal experiments carried out according to guidelines contained within the NSW
(Australia) Animal Research Act 1985, the NSW (Australia) Animal Research Regulation 2010 and the Australian code of practice
for the care and use of animals for scientific purposes, (8th Edition 2013, National Health and Medical Research Council (Australia)).
All experiments involving mice have been approved by the St. Vincent’s Campus Animal Research Committee AEC #14/27, #17/03




Two different genetically engineeredmousemodels were used in this study: MMTV-PolyomaMiddle T antigen (PyMT/WT) andmam-
mary restricted (MMTV) doxycycline-inducible (rtTA) Elf5 expression mouse (PyMT/ELF5) (see Figure S1 for breeding strategy).
PyMT/WT mouse model (gift from Dr. William J. Muller, McGill University) has been previously described (Guy et al., 1992; Lin
et al., 2003; Maglione et al., 2001). The PyMT/ELF5 model was generated by crossing the MMTV-PyMT with the doxycycline
(DOX) inducible Elf5 Knock In mouse line (Oakes et al., 2008) as previously described (Gallego-Ortega et al., 2015). Briefly, Elf5 trans-
gene expression is controlled by a doxycycline inducible promoter (TetON, tetracycline response element) and the expression of the
tetracycline transactivator protein (rtTA) is controlled by the MMTV promoter, a mammary-epithelium specific promoter. Elf5 expres-
sion was specifically induced in mammary epithelial cells since puberty of female mice (6 weeks-old) through doxycycline containing
food (700 mg/Kg of Doxycycline, Gordon’s Specialty Stockfeeds) as performed previously (Gallego-Ortega et al., 2015). At ethical
endpoint, (10% ± 3% tumor/body weight, which approximately corresponds to 14-week-old animals) PyMT/WT and PyMT/ELF5
were euthanized and size-matched tumors harvested and processed for single cell digestions (see below). Genotyping was per-
formed at theGarvanMolecular Genetics facility (NATA accredited, ISO 17025) by PCRof DNA extracted from themouse tail tip using
three set of primers: Elf5/EGFP (GCACCATCTTCTTCAAGGACGAC and GGTCTTTGCTCAGGGCGGAC), rtTA/MTB (TGCCGCCAT
TATTACGACAAGC and ACCGTACTCGTCAATTCCAAGGG) and PyMT (CGGCGGAGCGAGGAACTGAGGAGAG and TCAGAA
GACTCGGCAGTCTTAGGCG). The touchdown PCR conditions were 94C for 10 s of initial denaturation, followed by 10 cycles of
94C 10 s, 65-55C for 30 s and 72C for 1 min and 10 s and then 31 cycles of 94C 10 s, 55C for 30 s and 72C for 1 min and
10 s; the final extension is 72C for 3 minutes. All animals used in this study are heterozygous for Elf5, MTB, and PyMT (PyMT/
Elf5) or heterozygous for PyMT and MTB or heterozygous only for PyMT (PyMT/WT).
Animals for mammary gland differentiation series
Adult female mice (8-10 weeks old) were timed mated and pregnancy confirmed by visualizing a vaginal plug on the morning after
mating (0.5 days post coitum (d.p.c)). Inguinal mammary gland wholemounts were prepared from pregnant dams at 18.5 d.p.c or
at 4.5 days post-partum (established lactation) or after 1 or 4 days after forced involution. For post-partum and involution time points,
litters were normalized to 7 and forced involution induced by removal of pups at 10.5 days post-partum respectively. Inguinal mam-
mary gland wholemounts from 8-10-week-old virgin female mice were used as control.
METHOD DETAILS
Tumor digestion
Mammary tumors were collected from aged-matched MMTV-PyMT mice at 14 weeks of age, when tumor weights were 10 ± 3% of
total weight, no noticeable differences in tumor sizes were observed between genotypes according to previous results (Gallego-Or-
tega et al., 2015). Areas of necrosis were excluded, and only regions of epithelial mammary carcinomas were used for digestion and
analysis. Tumors were manually dissected into 3-5mm pieces using a surgical scalpel blade before being chopped to 100 mm with
maximum blade force on a McIlwain Tissue chopper. Tumor samples were incubated with 15,000 U of collagenase (Sigma Aldrich
Cat# C9891) and 5,000 U of hyaluronidase (Sigma Aldrich Cat# H3506) dissolved in DMEM high glucose with 5% FBS at 37C
shaking in 220 rpm for 1 hour. Samples were briefly disrupted with a pipette every 15 min during the incubation time to ensure
the tissues were sufficiently resuspended. 0.25% trypsin (GIBCO Cat# 15090-046) in 1mM EGTA was used to digest the samples
for 1min in 37C waterbath before proceeding with a 5-minute incubation with 5mg/mL of dispase (Roche Cat# 04942078001) dis-
solved in PBS in 37C waterbath. Red blood cells were then lysed with 0.8% ammonium chloride (Sigma Aldrich Cat# A9434) dis-
solved in water for 5 min in 37C waterbath. Samples were washed with PBS containing 2% FBS and spun at 1200 rpm for 5min
at 4Cbetween each step. The supernatant was aspirated and 1mg/mLDNase I (RocheCat# 10104159001) wasmixedwith the sam-
ple before incubation with each step. Finally, cells were filtered through a 40 mM nylon mesh (Corning) and resuspended in PBS with
2% FBS. Alive cells were selected using the Auto macs clean up procedure explained below.
An overview of the experimental design for the Drop-seq study on PyMT/WT and /ELF5 tumors is shown in Figure S2A, a total of 5
mammary carcinomas for PyMT/WT and 6 for PyMT/ELF5 genotypewere used for the Drop-seq study. Figure S2B showsQC cut offs
and Figure S2C shows the cell distribution in a tSNE plot and reveals no batch effect due to individual tumors within each genotype
with the exemption of WT#5 that contains a higher proportion of T cells, that sole form cluster 3 in Figure 1E. This noticeable increase
of T cells is likely caused by the incorporation of a proximal lymph node during cell preparation of this particular tumor. Importantly
this cluster did not drive any of the conclusions of this study.
Auto macs clean up
The viability of the cells was assessed by FACS. All tumors that contained less than 80%alive cells were labeled with Annexin specific
MACS beads using the Dead Cell Removal Kit (Miltenyi Biotec Cat# 130-090-101) following themanufacturers’ instructions and dead
cells were removed by passing the labeled cells through the autoMACS Pro (Miltenyi) (see more details at Salomon et al., 2019). A
preparation of cells containing a high proportion of viable cells (> 85% viability assessed by DAPI in FACS) were loaded into the mi-




Cells were captured using themicrofluidic devices described for Drop-seq (Macosko et al., 2015) following the Online Drop-seq Lab-
oratory Protocol version 3.1 (http://mccarrolllab.com/dropseq/) with somemodifications explained here. Briefly, to build the in-house
Drop-seq device, we purchased the PDMS co-flowmicrofluidic droplet generation chip from FlowJem using the CAD file design from
Macosko et al.; three syringe pumps (Legato 100 syringe pump, KD Scientific Cat# KDS-788100) and a magnetic bead mixer (VP
Cat# 772DP-N42-5-2). Tumor-dissociated single cells at 75 cells/ml in 0.01% BSA in PBS were loaded into one of the syringes; the
Drop-seq barcoded beads in lysis buffer (6% Ficoll PM-400, 0.2% Sarkosyl, 20mM EDTA, 200 mM Tris pH 7.5 and 50 mM DTT) at
280,000 beads/ml, under constant suspension with the magnetic bead mixer, were loaded in the second syringe, and the third sy-
ringe contained the droplet generation oil (Bio-Rad Cat# 186-4006). Flow rates were set for 4 ml/hour for the bead and cell suspen-
sions, and 15 ml/hour for the oil, resulting in105 mmdiameter droplets. We performed cell-bead droplet captures of 7 min to obtain
0.5ml of beads that will capture between 3000 to 3,500 cells or STAMPs (2.5% of beads containing a cell). The generated droplets
were broken by adding perfluorooctanol (Sigma Cat# 370533) in 6X SCC and washed in 6X SSC. The beads with barcoded RNAs
were retrotranscribed (Maxima H-Reverse transcriptase, ThermoFisher Scientific Cat# EP0753 using TSO primer, see Table S4)
and treated with exonuclease I (New England BioLabs Cat# M0293S). The beads containing cDNA were then washed, counted
and split to perform PCR amplification, we put 4000 beads (to generate approximately 100 STAMPs) per PCR (KAPA HiFi HotStart
ReadyMix PCR kit, KAPABIOSYSTEMS Cat# KR0370 and primer ‘‘TSO_PCR’’ from Table S4), the PCR program was the same than
Drop-seq lab protocol (v 3.1). The PCRs were purified using AMPure XP beads (Beckman Coulter Cat# A63882) at a 0.6X ratio
following the manufactures’ instructions. Pooled PCRs per sample were checked for quality, fragment size and concentration using
the Agilent High Sensitivity DNA Kit (Agilent Cat# 5067-4626) and run in the 2100 Bioanalyzer Instrument (Agilent). A total of 600 pg of
cDNA were then tagmented using the reagents from Nextera XT DNA Library kit (Illumina Cat# FC-131-1024) but following Macosko
et al. specifications and custom primers (Table S4, P5-TSO_Hybrid and N70X, the later primer sets for multiplexing). The tagmented
libraries were purified doing two rounds of clean ups with AMPure XP beads, the first one at a ratio of 0.6X and a second one at a ratio
of 1X and eluted in 10 ml H2O. The tagmented and multiplexed cDNA libraries were sequenced in Nextseq 500 using Nextseq 500
High Output v.2 kit (75 cycles, Illumina Cat# FC-404-2005) following Macosko et al. recommendations (see Table S4 for the custom
sequencing primer,’’ Read1CustomSeqB’’) with the following modifications. Drop-seq denatured libraries were loaded at 1.3pM final
concentration and were spiked in with 10% of 1.8pM PhiX Control v3 (Illumina Cat# FC-110-3001). Sequencing specifications were
as follows: 26bp Read1, 51bp Read 2 and single Nextera indexing (8bp). A total of3,000 cells or STAMPs/ per run were sequenced.
Flow cytometry analysis
Flow cytometry analysis were performed on BD FACSymphonyTM High-Speed Cell Analyzer or the FACSAriaIII (Becton Dickinson)
following automated compensation (FACSDiVa) using a 100um nozzle. Unspecific binding was prevented using 1:80 of Mouse BD Fc
Block (BD Biosciences, CA, USA, Cat# 553141) and 1:500 of Rat GammaGlobulin (Jackson ImmunoResearch Laboratories Inc., PA,
USA, Cat# 012-000-002) in a buffer containing DNase I (100 mg/mL, RocheCat# 10104159001). Alive cells were assessed by negative
DAPI staining (0.5 mg/ml; Thermo Fisher Scientific Cat# D1306). Subsequent immunostaining was performed using the following flu-
orescently tagged antibodies and dilutions: anti-mouse CD49b (1:100, Biolegend Cat# 108915), anti-human/mouse CD49f (1:200,
Biolegend Cat# 313615), anti-mouse Ly-6A/E (1:100, Biolegend Cat# 108125), anti-mouse CD45 (1:400, Biolegend Cat# 103114),
anti-mouse Ep-CAM (1:600, Biolegend Cat# 118205) and anti-Mouse CD31 (1:40, BD PharMingen Cat# 562861). Data was analyzed
using FlowJo software (version 10.4.2).
Drop-seq data processing
The sequencing output was analyzed using the McCaroll lab core computational protocol with a custom genome (mm10 plus Trinity
assemblies of transgene sequences [Grabherr et al., 2011]) and gene annotation (gencode vM14 plus). Seurat (v Seurat_2.3.4 [Butler
et al., 2018]) was the main platform for downstream analysis.
A total of 26,613 cells were sequenced (18,828 fromWT tumors and 7,785 from ELF5 tumors) (Figure S2A). First, we removed low-
quality cells bymodeling mitochondrial to nuclear gene content to < 15%(Macosko et al., 2015) and considering differences between
homeostatic tissues and tumors. We subsequently removed outlier cells that contained more than 4,000 genes as they could poten-
tially constitute cell doublets (Figure S2B). Thus, DGE matrices were trimmed for quality metrics (> 200 genes, < 15% mitochondrial
genes, and identified genes expressed in at least 3 cells), as a result 15,702 high quality cells (11,490 PyMT/WT and 4,212 PyMT/
ELF5) with a total of 28,945 genes proceeded with downstream analysis. A total of 6,176 informative genes were identified based
on expression and variance and organized into principal components. Two thirds of the total variation of the system was defined
by the first 20 PCs. Downstream analysis was performed according to Butler et al. with UMI number regression and 20 principal com-
ponents of variable genes being used for dimensional reduction (tSNE) and cluster calling (Butler et al., 2018) (Figure S2C). Elf5
expression was restricted to the PyMT/ELF5 tumors (Figure S2D). PyMT tumors are derived from the signal of the Polyoma
middle-T oncogene in congenic FBVn animals of pure background, thus the effects of the environment are minimized as the individ-




Clustering tree (Zappia and Oshlack, 2018) was employed in conjunction with cluster validation, and split error estimation across a
range of clustering resolutions to identify optimal resolution values. CCA was performed on experiments split by genotype using the
union of the top 2000 variable genes for each genotype. No cells were discarded from downstream analysis to retain unique subpop-
ulations between the experiments and downstream analysis was performed as above using CCA in place of PCA.
Monocle
Monocle (v2 ole (Trapnell et al., 2014)) was used to assemble cells assigned to epithelial clusters along a pseudotime vector gener-
ated from single cell expression of ‘‘Gorsmy’’ (Pal et al., 2017). States were assigned using DDRTree according to the manual.
Gene set variation analysis
GSVA (Hänzelmann et al., 2013) was calculated for averaged expression values for clusters or Poisson distributed counts data using
gene mouse hallmark gene lists downloaded from http://bioinf.wehi.edu.au/software/MSigDB (Subramanian et al., 2005; Mootha
et al., 2003).
Metasignatures
Metasignatures were generated by calculating the sum of scaled expression scores for all genes nominated for the signature in each
cell. The relative contribution of each gene to the score was used to rank genes in the signature.
Tumor protein isolation and western blot
Tumor pieces of amaximum of 0.5 cm x 0.5 cmwere lysed in 200 ul of tissue lysis buffer (1.5mMMgCl2, 0.2mMEDTA, 0.3mMNaCl,
25 mM HEPES pH 7.5, 20 mM b-glycerophosphate, 0.1% Triton X-100) supplemented with a cocktail of protease/phosphatase in-
hibitors (100 mg/ml PMSF, 0.5 mM DTT, protease cocktail Roche Cat# 11836170001, phosphatase cocktail Roche Cat#
04906845001) and 400 U/ml of Benzonase nuclease (Sigma-Aldrich Cat# 9025-65-4). Tumor chunks in the lysis buffer were ho-
mogenized using a dounce homogenizer with tight pestle at 4C until the tissue was completely dissolved. Lysed tumors were cen-
trifugated at 1,400 rpm for 20 min at 4C and the supernatant was incubated at room temperature for 1 hour under rotation. Then the
sample was centrifugated at 8000 rpm for 10 min at 4C and the aqueous phase was isolated and quantitated for total protein using
Bradford protein assay (Bio-Rad Cat# 5000002) following manufacturer’s instructions.
40 ug of protein lysates were prepared in Invitrogen LDS sample buffer (Cat# NP0007 (4X)) plus Sample Reducing Agent (Invitrogen
Cat# NP0004 10X) and separated on precast NuPAGE 4 to 12% Bis-Tris acrylamide gels (Thermo Fisher Scientific, Cat# NP0322) in
MOPS buffer, transferred to a PVDF membrane (Bio-Rad). Membranes were blocked with 5% skim milk in TBS-Tween buffer for 1
hour at room temperature, primary antibody for 2 hours at room temperature ors overnight at 4C, and a horseradish peroxidase
(HRP)-linked secondary antibody for 1 hour at room temperature. The primary antibodies used were: anti-Elf5 (N-20) (1:500, Santa
Cruz Cat# sc-9645), anti-vimentin (1:1000, Leica Biosystems Cat# VIM-572-L-CE), anti-E-cadherin (1:10,000, BD Biosciences Cat#
610181), anti-b-Actin (1:2000, Sigma-Aldrich Cat# A1978). Secondary antibodies were HRP-donkey anti-goat (1: 1000, Santa Cruz
Cat# sc-2020) and HRP-sheep anti-mouse (1:5000, Amersham Biosciences, Cat# 25005363).
Chemiluminescence detection was done using Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate kit (Perkin-
Elmer Cat# NEL103E001EA) on Fuji Medical X-ray Film (Fujifilm).
Immunohistochemistry
IHC was performed at the Garvan’s Histopathology facility. Mouse mammary glands at different stages of development from FVB/N
mice and mammary tumors and lungs from PyMT/WT and PyMT/ELF5 mice were fixed, defatted, dehydrated, and paraffin
embedded using the Leica Peloris II tissue processor following the manufacturers’ recommendations. The paraffin embedded tis-
sues were cut into 4-mm sections using the Leica Microtome RM2235 and placed on glass microscope slides. These slides were
stained for hematoxylin and eosin (H&E), or immunostained using the fully automated Leica BondRX. Briefly, sectionswere deparaffi-
nized in xylene and rehydrated in ethanol grading; antigen retrieval was performed using the heat-induced epitope retrieval method
either using the BOND Epitope Retrieval Solution 1 (pH 6.0) (Leica Cat# AR9961) or BOND Epitope Retrieval Solution 2 (pH 9.0) (Leica
Cat# AR9640) for 30 min, peroxidase quenching was performed with 3%H2O2. The primary antibodies were incubated for 1 h: Anti-
COL1A1 (1:200, Cell Signaling Cat# 39952), -MMP3 (1:100, Abcam Cat# ab52915) and -CXCL12/SDF1 (1:500, Abcam Cat# ab9797)
and the Leica BOND Polymer Refine Detection kit (Cat# DS9800) was used as secondary detection method.
For the immunostaining of milk in mammary tumors andmammary glands, antigen retrieval was done in a water bath for 20 mins in
citrate buffer, pH 6.0 (Dako Cat# S1699) and the next steps for the immunostaining were done using the Dako Autostainer. The rabbit
anti-mouse milk proteins primary antibody (1:12,000, Accurate Chemical & Scientific CO, Cat# YNRMTM) was incubated for 1h fol-
lowed by 30-min incubation of EnVision+ System/HRP Rabbit (Dako, Cat# K4009). Antigen visualization was carried out using the
Liquid DAB+ Substrate chromogen system (Cat# K3467).Cell Reports 35, 108945, April 13, 2021 e6
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Paraffin-embedded samples were cut into 4 mm sections and stained with 0.1% picrosirius red for fibrillar collagen (Direct Red 80,
Sigma Cat# 365548) according to manufacturer’s instructions. As previously performed (Cazet et al., 2018; Vennin et al., 2017) polar-
ized light imaging was performed on a Leica DM6000 fitted with a polarizer in combination with a transmitted light analyzer. The rela-
tive area of red-orange (high birefringent) fibers, yellow (medium birefringent) fibers, and green (low birefringent) fibers (as a%of total
fibers) was calculated.
Hypoxia analysis
Hypoxia analysis were performed using the Hypoxyprobe Plus Kit (HypoxyprobeTM Cat# HP2-200Kit) following the manufactures’
instructions. Briefly, 60 mg/kg body weight of pimonidazole HCL (HypoxyprobeTM-1) were intraperitoneally injected into PyMT/
WT and PyMT/Elf5 animals at ethical endpoint (at 14 weeks). Tumors and lungs were harvested the next day after pimonidazole
HCL injection and were fixed in 10% neutral-buffered formalin overnight. FFPE tissues were sectioned to 4mm for IHC staining as
described above. FITC conjugated to anti-pimonidazole mouse IgG1 monoclonal antibody (FITC-MAb1, clone 4.3.11.3) at 1:1000
and a peroxidase conjugated rabbit anti-FITC as a secondary reagent (1:100) were used to stain for the protein adducts of pimoni-
dazole in hypoxic tissue.
Cell to cell communication prediction
CellphoneDB (Vento-Tormo et al., 2018) (https://www.cellphonedb.org/) was performed for 100 cells expressing the highest number
of genes in each cluster. A specific interaction was considered as significant if p < 0.01 and mean score > 0.3. Expression values of
ligand/receptor gene pairs were plotted using Seurat DotPlot function for all cells in each cluster. Interactome of Figure 7Bwas gener-
ated using the parameters of more than 10 significant interactions with a mean score greater than 0.3, number cut as more than 10
connections and number split 10.
Multiphoton microscopy
Second Harmonic Generation (SHG) signal was acquired using a 25x 0.95 NA water objective on an inverted Leica DMI 6000 SP8
confocal microscope. Excitation source was a Ti:Sapphire femtosecond laser cavity (Coherent Chameleon Ultra II), tuned to a wave-
length of 880 nm and operating at 80MHz. Signal intensity was recorded with RLDHyD detectors (420/40 nm)). For tumor samples, 5
representative regions of interest (512 mmx512 mm) per tumorwere imaged, for CDMs 3 representative areas of 3 technical replicates
over a 3D z stack (20 mm depth; 20 mm depth for CDM, with a z-step size of 1.26 mm). SHG signal coverage in tumor samples was
measured with ImageJ (National Institutes of Health, Bethesda, MD, USA). For CDMs mean SHG intensity was measured using
MATLAB (Mathworks). Representative images of maximum projections are shown.
Blood vessel patency analysis was performed injecting 10 ml of quantum dots blood tracers (Qtracker 655 Vascular Labels, Thermo
Fisher Scientific Cat# Q21021MP) through the tail vein of the animals (Video S1 and S2). Images were acquired with a 25x NA0.95
water objective. A dichroic filter (560 nm) was used to separate the GFP signal from quantum dot emission, which were further
selected with band pass filters (525/50 and 617/73, respectively).
Immunofluorescence
Mammary tumors from PyMT/WT and PyMT/ELF5 animals were harvested at ethical endpoint and frozen in Tissue-Tek O.C.T.
Compound (Sakura Cat# 4583). Cut frozen sections (8 mm) were air-dried for 30 minutes and then fixed in 4% paraformaldehyde
(PFA) for 5 minutes. After washing 3 times with PBS, the sections were blocked in serum free protein block (Dako Cat# X0909) for
60 minutes. Sections were stained with anti-CD31 antibody (1:400, BD PharMingen Cat# 550274) overnight at 4C. After washing,
the samples were blocked in serum free protein block for 5 minutes. Then, the samples were incubated for 1 hour in secondary anti-
body (1:600, Goat-anti-rat Alexa Fluor 647, Invitrogen Cat# a-21247). The samples were washed and incubated for 10 minutes in
DAPI (1:1000, Thermo Fisher Scientific Cat# D1306). After washing, the sections were covered with coverslips using mounting me-
dium (Confocal Matrix Micro Tech Lab). The sections were analyzed and photographed one day after mounting them, using the
fluorescent microscope (Leica DM 5500).
Clinical samples and survival analysis
We used the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) (Curtis et al., 2012; Pereira et al., 2016)
dataset and the TCGA (The Cancer Genome Atlas) dataset (Berger et al., 2018; Cancer Genome Atlas, 2012; Ciriello et al., 2015)
for patient survival analysis. These datasets contain RNaseq and microarray data as well as detailed clinical information from breast
cancer patients. Data was accessed using cBioPortal (https://www.cbioportal.org/) (Gao et al., 2013; Cerami et al., 2012).
Patient survival analysis was performed using the ‘‘survminer’’ package (https://github.com/kassambara/survminer). Survival
Curves were drawn using ‘ggplot20. R package version 0.4.3 on METABRIC data accessed from the R-Based API for Accessing
the MSKCC Cancer Genomics Data Server, CGDSR (R package cgdsr version 1.2.10). Cohorts were split by ELF5 expression
and then by metascores and overall survival was compared by cox proportional hazards analysis.e7 Cell Reports 35, 108945, April 13, 2021
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Statistical details for sample size and the threshold for statistical significance can be found in the figure legends. Unless otherwise
stated in the figure legend and or method details, data in bar graphs are expressed as mean ± SEM and the statistical test was un-
paired t test. Data represented as boxplot show the minimum and maximum (whiskers); the median of the lower half of the dataset
(quartile 1), the median and the median of the upper half of the dataset (quartile 3) (box).
Quantification of the hypoxia assays and IHC was performed using Andy’s DAB Algorithm (Law et al., 2017) through FIJI (ImageJ).
CDMsmean SHG intensity wasmeasured usingMATLAB (Mathworks). Quantitative intensity measurements of fibrillar collagen con-
tent and birefringent signal were carried out using in house scripts in ImageJ and can be found in https://github.com/GaldesLab/
CellReportsManuscript and https://github.com/TCox-Lab/PicRed_Biref and https://github.com/TCox-Lab/Collagen_Orientation .
The graphs and statistical analyses associated were performed using GraphPad Prism.
ADDITIONAL RESOURCES
An interactive Shiny clustering tool of the Drop-seq datasets was developed to enable the access and analysis of the data in a user-
friendly and interactive manner. The website can be found at https://galdeslab.github.io/CellReportsManuscript/PyMT.html.Cell Reports 35, 108945, April 13, 2021 e8
